New ways to treat diseases
Our group operates as a joint laboratory, a synergistic partnership between the University of Milan (UNIMI) and the National Institute of Molecular Genetics (INGM). This collaboration leverages the distinct strengths of both institutions to advance our research interests.
The central focus of our research is the development and adaptation of cutting-edge gene editing technologies for both fundamental laboratory investigations and translational therapeutic applications. We are dedicated to establishing innovative therapeutic interventions for a range of diseases, employing two complementary strategies: (i) the engineering of extracellular vesicles for efficient and targeted delivery of gene editing tools or variety of therapeutic proteins, and (ii) the precise manipulation of human lymphocyte activation and effector mechanisms to potentiate next-generation lymphocyte-based immunotherapies.
It was his first oral presentation in a scientific event and he won the “best oral presentation” award at EVIta 2026, in Como! Alessio shocked the audience sharing the promising...
Read more
Our postdoc Silvia Fiori presented her last findings about cellular therapies and CRISPR/Cas9 engineering at the 33rd Annual Congress of the European Society of Gene and Cell Therapy (ESGCT 2026),...
Read more
Another milestone accomplished in the Albanese Lab. We try to do great science, but as important as that, we try to form a new generation of good scientists. Congrats to...
Read more